| Name |
Title |
|---|
| 0101 |
Fluconazole versus Voriconazole after Allogeneic Transplantation |
| 0102 |
Autologous/Autologous versus Autologous/Allogeneic Transplantation for Multiple Myeloma |
| 0201 |
Peripheral Blood versus Bone Marrow Grafts from Unrelated Donors |
| 0202 |
Autologous versus Nonmyeloablative Allogeneic Transplantation for Follicular Lymphoma |
| 0301 |
Conditioning Regimens in Unrelated Donor Transplantation for Aplastic Anemia |
| 0302 |
Randomized Trial of Acute GVHD Therapies |
| 0303 |
T-Cell Depleted Peripheral Blood Stem Cell Transplantation for AML |
| 0401 |
Rituxan/BEAM versus Bexxar/BEAM with Autologous Transplantation in Diffuse Large Cell Lymphoma |
| 0402 |
0402Tacrolimus/Sirolimus versus Tacrolimus/Methotrexate as GVHD Prophylaxis |
| 0403 |
Etanercept for Idiopathic Pneumonia Syndrome |
| 0501 |
Single versus Double Cord Blood Transplantation in Children |
| 0502 |
Reduced-Intensity Conditioning in Transplantation for AML in the Elderly |
| 0601 |
Transplantation Using Reduced-Intensity Conditioning and Unrelated Donor Graft for Children with Severe Sickle Cell Disease |
| 0603 |
Haploidentical Transplantation with Reduced-Intensity Conditioning |
| 0604 |
Double Cord Blood Transplantation with Reduced-Intensity Conditioning |
| 0701 |
Transplantation using Reduced-Intensity Conditioning for Relapsed Follicular Lymphoma |
| 0702 |
Autologous Transplantation with/without Consolidation versus Tandem Autologous Transplantation with Lenalidomide Maintenance |
07LT
| Continued Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients Who Have Enrolled on BMT CTN 0702
|
| 0703 |
Tandem Autologous Transplantation for Recurrent Hodgkin Disease |
| 0704 |
Maintenance Therapy with CC-5013 or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma |
| 0801 |
Randomized Trial using Sirolimus with Other Agents for Chronic GVHD |
| 0802 |
Corticosteroids with Mycophenolate Mofetil versus Corticosteroids with Placebo as Initial Systemic Treatment of Acute GVHD |
| 0803 |
High Dose Chemotherapy with Autologous Stem Cell Rescue for Aggressive B cell Lymphoma and Hodgkin Lymphoma in HIV-infected Patients |
| 0804 |
Phase II Study of Reduced-intensity Allogeneic Stem Cell Transplantation for High Risk Chronic Lymphocytic Leukemia |
| 0805 |
Hyper-CVAD and Dasatinib with or without Allogeneic Stem Cell transplant in Patients with Philadelphia (Ph) Chromosome Positive and/or Bcr-Abl Positive Acute Lymphoblastic Leukemia |
| 0901 |
Myeloablative versus Nonmyeloablative Transplant Conditioning in Patients with Myelodysplastic Syndrome or Acute Myelogenous Leukemia |
| 0902 |
Peri-transplant Stress Management |
| 0903 |
Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodyplastic Syndromes in HIV-infected Patients |
1101
| A Multi-Center, Phase III, Randomized Trial of Reduced Intensity(RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (Haplo) for Patients with Hematologic Malignancies
|
1102
| A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Tranplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome
|
| 1202 | Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic HCT
|
| 1203 |
PROGRESS I: A Multi-center Phase II Trial Randomizing Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls |
| 1204 |
Reduced-intensity Conditioning for Children and Adults with Hemophagocytic Syndromes or Selected Primary Immune Deficiencies |
| 1205 | Easy-to-Read Informed Consent (ETRIC) for Hematopoietic Cell Transplantation Clinical Trials. |
1301
| A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease
|
1302
| Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma
|
| 1304 | DETERMINATION; DFCI 10-106: A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age
|
1401
| A Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma with or without Vaccination with Dendritic Cell/Myeloma Fusions
|
| 1501 | A Randomized, Phase II, Multicenter, Open Label, Study Evaluating Sirolimus and Prednisone in Patients with Refined Minnesota Standard Risk, Ann Arbor 1/2 Confirmed Acute Graft-Versus-Host Disease |
| 1505 | A Randomized Intervention Trial |
